FIGURE 3.
Patterns of continued and delayed response by the level of initial response at Month 1 after treatment with erenumab 70 and 140 mg. (A) Response at Month 2 or 3. (B) Response at Months 2 and 3. MMD, monthly migraine day
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.